Given the critical role of MET amplification in advanced EGFR-mutant NSCLC at EGFR-TKI first-line treatment failure and the controversy surrounding detection methods due to small sample sizes and high false-negative rates reported in previous studies,31 evaluating concordance among assay methods may inform alternatives to FISH. This evidence concerns the gene EGFR and non-small cell lung carcinoma.